Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Advanced pancreatic cancer patients have poor prognosis and scarcely respond to conventional therapies. Clinical trials support the use of molecular-targeted therapy against epidermal growth factor receptor (EGFR) signaling. The objective of the current study was to evaluate the contribution of a monoclonal antibody against EGFR, nimotuzumab, to standard gemcitabine therapy. Patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma were assigned to receive gemcitabine plus nimotuzumab. The primary end point was overall survival, whereas the secondary end points included progression-free survival, objective response, and adverse side effects. A total of 18 eligible patients were accrued between December 2007 and July 2010. The disease control rate, calculated as the sum of complete response, partial response, and stable disease, was 55.6 %. The median overall survival time was 9.29 months (95 % CI, 5.499 to 13.072). The median progression-free survival was 3.71 months (95 % CI, 2.526 to 4.902), and the 1-year survival rate was 38.9 %. Of all the patients, 88.8 % had at least one adverse side effect; however, no grade 4 adverse side effect was reported. Nimotuzumab as a high-purity humanized monoclonal antibody with favorable safety profile, its value in the treatment of pancreatic cancer along with gemcitabine, particularly in the comprehensive treatment of advanced pancreatic cancer, is appealing for further prospective randomized large-scale clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. GLOBOCAN. Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008. 2008; http://globocan.iarc.fr/. Accessed 15 March 2013.

  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  3. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049–57.

    Article  PubMed  CAS  Google Scholar 

  4. O'Sullivan A, Kocher HM. Pancreatic cancer. Br Med J Clin Evid. 2007;11:409–37.

    Google Scholar 

  5. Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128:1626–41.

    Article  PubMed  Google Scholar 

  6. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485–9.

    Article  PubMed  CAS  Google Scholar 

  7. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

    PubMed  CAS  Google Scholar 

  8. Hu J, Zhao G, Wang HX, et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol. 2011;4:11.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Strimpakos AS, Syrigos KN, Saif MW. Novel agents in early phase clinical studies on refractory pancreatic cancer. JOP. 2012;13:166–8.

    PubMed  Google Scholar 

  10. Lowery MA, O'Reilly EM. Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J. 2012;12:1–9.

    Article  PubMed  CAS  Google Scholar 

  11. Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm. 2011;68:573–84.

    Article  PubMed  Google Scholar 

  12. Yip D, Karapetis C, Strickland A, et al. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2009;4:CD002093.

    Google Scholar 

  13. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics: Targets & Therapy. 2008;2:83–95.

    CAS  Google Scholar 

  14. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.

    Article  PubMed  CAS  Google Scholar 

  15. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232.

    Article  PubMed  CAS  Google Scholar 

  16. Troiani T, Martinelli E, Capasso A, et al. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets. 2012;13:802–10.

    Article  PubMed  CAS  Google Scholar 

  17. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev. 2012;38:843–53.

    Article  PubMed  CAS  Google Scholar 

  18. Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology. 2012;83:117–27.

    Article  PubMed  CAS  Google Scholar 

  19. Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69:5851–9.

    Article  PubMed  CAS  Google Scholar 

  20. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR mono-clonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther. 2009;9:1199–206.

    Article  PubMed  CAS  Google Scholar 

  21. Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012;30:1138–43.

    Article  PubMed  CAS  Google Scholar 

  22. Strumberg D, Schultheis B, Scheulen ME, et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther. 2010;48:473–5.

    Article  PubMed  CAS  Google Scholar 

  23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  24. Eltawil KM, Renfrew PD, Molinari M. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford). 2012;14:260–8.

    Article  Google Scholar 

  25. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Rivera F, Vega-Villegas ME, Lopez-Brea MF, et al. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. 2008;47:9–19.

    Article  PubMed  CAS  Google Scholar 

  27. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol. 2005;23:16s.

    Google Scholar 

  28. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.

    Article  PubMed  CAS  Google Scholar 

  29. Faloppi L, Andrikou K, Cascinu S. Cetuximab: still an option in the treatment of pancreatic cancer? Expert Opin Biol Ther. 2013;13:791–801.

    Article  PubMed  CAS  Google Scholar 

  30. Fensterer H, Schade-Brittinger C, Müller HH, et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013;24:2576–81.

    Article  PubMed  CAS  Google Scholar 

  31. Cheng YJ, Bai CM, Zhang ZJ. Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer. Acta Acad Med Sin. 2010;32:421–3.

    CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Oncology Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China

    Dan Su, Shun-Chang Jiao, Li-Jie Wang, Wei-Wei Shi, Yan-Yan Long, Juan Li & Li Bai

Authors
  1. Dan Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shun-Chang Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-Jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei-Wei Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan-Yan Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Bai.

Additional information

Dan Su and Shun-Chang Jiao contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Su, D., Jiao, SC., Wang, LJ. et al. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumor Biol. 35, 2313–2318 (2014). https://doi.org/10.1007/s13277-013-1306-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1306-x

Keywords

Search

Navigation